CAR T-Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

Fairfield Market Research, a leading market research firm, has released a comprehensive analysis of the CAR T-cell therapy market, forecasting continued growth in the sector. According to the latest industry study, the global CAR T-cell therapy market valued is projected to reach US$ 2.8 billion by 2031.

Rising Demand for CAR T-Cell Therapy Fuelled by Advancements in Cancer Treatment

CAR T-cell therapy, a revolutionary approach in cancer treatment, has garnered significant attention and investment in recent years. This therapy involves extracting T-cells from a patient's blood, modifying them in a lab by adding a gene for a man-made receptor called a chimeric antigen receptor (CAR), and reintroducing these engineered cells back into the patient's body. By enhancing the recognition of specific cancer cell antigens, CAR T-cells offer a promising avenue for targeted cancer therapy.

The persistent increase in the prevalence of cancer globally has been a key driver for the growing demand for CAR T-cell therapy. Moreover, advancements in research and development in the life sciences and biotechnology sectors have paved the way for the exploration of artificial T-cell receptors and chimeric immunoreceptors, further expanding the therapeutic potential of CAR T-cell therapy across various types of cancer.

Key Opportunities and Market Insights

Market players involved in CAR T-cell therapy are presented with several opportunities for growth and innovation. The emphasis on research and development for treating various types of cancers, including lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer, is expected to create significant avenues for expansion in the CAR T-cell therapy market. Additionally, favorable government policies and funding initiatives are likely to further propel the demand for CAR T-cell therapy in the foreseeable future.

Regional Outlook: U.S. and Germany Lead the Way

The United States remains a pivotal market for CAR T-cell therapy, with over 98% value share in the North American market. The increasing focus of life sciences companies on the development and commercial manufacturing of CAR T-cells, coupled with improvements in quality control systems, continues to drive demand in the U.S. market.

Germany emerges as a lucrative market for CAR T-cell therapy in Europe, expected to account for nearly 27% of the market share by 2031. Factors such as the aging population and favorable regulatory landscape contribute to the growing demand for CAR T-cell therapy in Germany.

Competitive Analysis

Key companies functioning in the market including:

Novartis AG
Gilead Sciences Inc.
Celgene Corporation
bluebird bio, Inc.

Car T-Cell Therapy Industry Research by Category

Product

Yescarta (axicabtagene ciloleucel)
Kymriah (tisagenlecleucel)
JCAR017 (lisocabtagene maraleucel)
bb2121

Indication

Relapsed Large B-cell Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Multiple Myeloma

End User

Car T-Cell Therapy at Hospitals
Car T-Cell Therapy at Cancer Treatment Centers

1. Executive Summary

1.1. Global CAR T-Cell Therapy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global CAR T-Cell Therapy Market Outlook, 2018 - 2031

3.1. Global CAR T-Cell Therapy Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Yescarta (axicabtagene ciloleucel)
  - 3.1.1.2. Kymriah (tisagenlecleucel)
  - 3.1.1.3. JCAR017 (lisocabtagene maraleucel)
  - 3.1.1.4. bb2121
3.2. Global CAR T-Cell Therapy Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Relapsed Large B-cell Lymphoma
  - 3.2.1.2. Acute Lymphoblastic Leukemia (ALL)
  - 3.2.1.3. Multiple Myeloma
3.3. Global CAR T-Cell Therapy Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospitals
  - 3.3.1.2. Cancer Treatment Centers
3.4. Global CAR T-Cell Therapy Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America CAR T-Cell Therapy Market Outlook, 2018 - 2031

4.1. North America CAR T-Cell Therapy Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Yescarta (axicabtagene ciloleucel)
  - 4.1.1.2. Kymriah (tisagenlecleucel)
  - 4.1.1.3. JCAR017 (lisocabtagene maraleucel)
  - 4.1.1.4. bb2121
4.2. North America CAR T-Cell Therapy Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Relapsed Large B-cell Lymphoma
  - 4.2.1.2. Acute Lymphoblastic Leukemia (ALL)
  - 4.2.1.3. Multiple Myeloma
4.3. North America CAR T-Cell Therapy Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospitals
  - 4.3.1.2. Cancer Treatment Centers
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America CAR T-Cell Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 4.4.1.2. U.S. CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 4.4.1.3. U.S. CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 4.4.1.4. Canada CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 4.4.1.5. Canada CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 4.4.1.6. Canada CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe CAR T-Cell Therapy Market Outlook, 2018 - 2031

5.1. Europe CAR T-Cell Therapy Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Yescarta (axicabtagene ciloleucel)
  - 5.1.1.2. Kymriah (tisagenlecleucel)
  - 5.1.1.3. JCAR017 (lisocabtagene maraleucel)
  - 5.1.1.4. bb2121
5.2. Europe CAR T-Cell Therapy Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Relapsed Large B-cell Lymphoma
  - 5.2.1.2. Acute Lymphoblastic Leukemia (ALL)
  - 5.2.1.3. Multiple Myeloma
5.3. Europe CAR T-Cell Therapy Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospitals
  - 5.3.1.2. Cancer Treatment Centers
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe CAR T-Cell Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.2. Germany CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.3. Germany CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.4.1.4. U.K. CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.5. U.K. CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.6. U.K. CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.4.1.7. France CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.8. France CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.9. France CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.4.1.10. Italy CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.11. Italy CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.12. Italy CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.4.1.13. Turkey CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.14. Turkey CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.15. Turkey CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.4.1.16. Russia CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.17. Russia CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.18. Russia CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 5.4.1.19. Rest of Europe CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 5.4.1.20. Rest of Europe CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 5.4.1.21. Rest of Europe CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific CAR T-Cell Therapy Market Outlook, 2018 - 2031

6.1. Asia Pacific CAR T-Cell Therapy Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Yescarta (axicabtagene ciloleucel)
  - 6.1.1.2. Kymriah (tisagenlecleucel)
  - 6.1.1.3. JCAR017 (lisocabtagene maraleucel)
  - 6.1.1.4. bb2121
6.2. Asia Pacific CAR T-Cell Therapy Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Relapsed Large B-cell Lymphoma
  - 6.2.1.2. Acute Lymphoblastic Leukemia (ALL)
  - 6.2.1.3. Multiple Myeloma
6.3. Asia Pacific CAR T-Cell Therapy Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospitals
  - 6.3.1.2. Cancer Treatment Centers
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific CAR T-Cell Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.4.1.2. China CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 6.4.1.3. China CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.4.1.4. Japan CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.4.1.5. Japan CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 6.4.1.6. Japan CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.4.1.7. South Korea CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.4.1.8. South Korea CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 6.4.1.9. South Korea CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.4.1.10. India CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.4.1.11. India CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 6.4.1.12. India CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.4.1.13. Southeast Asia CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.4.1.14. Southeast Asia CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 6.4.1.15. Southeast Asia CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America CAR T-Cell Therapy Market Outlook, 2018 - 2031

7.1. Latin America CAR T-Cell Therapy Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Yescarta (axicabtagene ciloleucel)
  - 7.1.1.2. Kymriah (tisagenlecleucel)
  - 7.1.1.3. JCAR017 (lisocabtagene maraleucel)
  - 7.1.1.4. bb2121
7.2. Latin America CAR T-Cell Therapy Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Relapsed Large B-cell Lymphoma
  - 7.2.1.2. Acute Lymphoblastic Leukemia (ALL)
  - 7.2.1.3. Multiple Myeloma
7.3. Latin America CAR T-Cell Therapy Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospitals
  - 7.3.1.2. Cancer Treatment Centers
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America CAR T-Cell Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.4.1.2. Brazil CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 7.4.1.3. Brazil CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.4.1.4. Mexico CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.4.1.5. Mexico CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 7.4.1.6. Mexico CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.4.1.7. Argentina CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.4.1.8. Argentina CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 7.4.1.9. Argentina CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa CAR T-Cell Therapy Market Outlook, 2018 - 2031

8.1. Middle East & Africa CAR T-Cell Therapy Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Yescarta (axicabtagene ciloleucel)
  - 8.1.1.2. Kymriah (tisagenlecleucel)
  - 8.1.1.3. JCAR017 (lisocabtagene maraleucel)
  - 8.1.1.4. bb2121
8.2. Middle East & Africa CAR T-Cell Therapy Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Relapsed Large B-cell Lymphoma
  - 8.2.1.2. Acute Lymphoblastic Leukemia (ALL)
  - 8.2.1.3. Multiple Myeloma
8.3. Middle East & Africa CAR T-Cell Therapy Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospitals
  - 8.3.1.2. Cancer Treatment Centers
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa CAR T-Cell Therapy Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.4.1.2. GCC CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 8.4.1.3. GCC CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.4.1.4. South Africa CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.4.1.5. South Africa CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 8.4.1.6. South Africa CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.4.1.7. Egypt CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.4.1.8. Egypt CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 8.4.1.9. Egypt CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.4.1.10. Nigeria CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.4.1.11. Nigeria CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 8.4.1.12. Nigeria CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa CAR T-Cell Therapy Market by Product, Value (US$ Mn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa CAR T-Cell Therapy Market by Indication, Value (US$ Mn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa CAR T-Cell Therapy Market by End User, Value (US$ Mn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By End User vs By Application Heat map
9.2. Manufacturer vs by Indication Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Novartis AG
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Gilead Sciences Inc.
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Celgene Corporation
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. bluebird bio, Inc.
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Celyad Oncology
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Cartesian Therapeutics
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Intellia Therapeutics
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Sorrento Therapeutics, Inc
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations